Evidence map›Paper›PMID 39423362›Full record

ArticleACS infectious diseases2024

Single-Dose Drug Development Candidate for Schistosomiasis.

Derek A Leas, Jennifer Keiser, Susan A Charman, David M Shackleford, Jeremy O Jones, Michael Campbell, Gong Chen, Kasiram Katneni, Rahul Patil, Meiyu Hu and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Derek A LeasCollege of Pharmacy, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 986125, United States.
Jennifer KeiserDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel CH-4002, Switzerland.
Susan A CharmanCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.ORCID 0000-0003-1753-8213
David M ShacklefordCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Jeremy O JonesDepartment of Cancer Biology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California 93534-7059, United States.
Michael CampbellCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Gong ChenCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Kasiram KatneniCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Rahul PatilCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Meiyu HuCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Thao PhamCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
Cécile HäberliDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel CH-4002, Switzerland.
Thomas T SchulzeDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska 68198-6125, United States.
Andrew J NevilleDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska 68198-6125, United States.ORCID 0000-0001-6237-9640
Xiaofang WangCollege of Pharmacy, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 986125, United States.
Yuxiang DongCollege of Pharmacy, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 986125, United States.ORCID 0000-0003-1412-3178
Paul H DavisDepartment of Biology, University of Nebraska at Omaha, Omaha, Nebraska 68198-6125, United States.ORCID 0000-0002-0526-3841
Jonathan L VennerstromCollege of Pharmacy, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, Nebraska 986125, United States.ORCID 0000-0003-0075-2336

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
Optimization of Antischistosomal ChemotypesR01AI116723 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VENNERSTROM, JONATHAN L · 2015 to 2024
$6.2M
Increasing the Antischistosomal Selectivity of Aryl HydantoinsR21AI097802 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI VENNERSTROM, JONATHAN L · 2012 to 2013
$358k
NIAID NIH HHS R01 AI116723NIAID NIH HHS R21 AI097802NIGMS NIH HHS P20 GM103427
6 · The paper itself

Abstract

Aryl hydantoins were identified in the early 1980s as a promising antischistosomal chemotype. However, as exemplified by Ro 13-3978, this compound series produced antiandrogenic side effects on the host, a not unexpected outcome given their structural similarity to the antiandrogenic drug nilutamide. The two key advances in our optimization of Ro 13-3978 were swapping the aryl trifluoromethyl substituent with a difluoroethyl to abolish antiandrogenic effects and replacing the hydrogen atoms of the

Indexed as

Drug DevelopmentSchistosomiasisAnimalsAnthelminticsHumansMiceSchistosomaSchistosoma mansoniSchistosomicidesStructure-Activity RelationshipAnthelminticsSchistosomicidesantiandrogenicantischistosomalaryl hydantoinstructure−activity relationship

Identifiers

PMID39423362
PMCPMC12930453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.